Steven E. Fleck

Director of Finance/CFO at CDG Therapeutics, Inc.

Health Technology

Consumer Services

Profile

Steven E.
Fleck has been Chief Financial Officer of CDG Therapeutics, Inc. since April, 2006.
Prior to CDG Therapeutics, he was Director of Accounting for Northfield Laboratories, Inc. from 1998 to 2005.
Mr. Fleck received a BA degree in Economics from the University of Illinois in 1984 and an MBA from Northern Illinois University in 1987.

Steven E. Fleck active positions

Companies	Position	Start
CDG Therapeutics, Inc. CDG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology CDG Therapeutics, Inc. develops pharmaceutical products. Its peptides are derived from bacterial & plant sources and are selective for certain cancers while avoiding healthy cells. The company was founded by Ananda M. Chakrabarty and Tapas K. Das Gupta in May 2001 and is located in River Forest, IL.	Director of Finance/CFO	2006-03-31

All active positions of Steven E. Fleck

Former positions of Steven E. Fleck

Companies	Position	End
Northfield Laboratories, Inc. Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage.	Comptroller/Controller/Auditor	2004-12-31

See the detail of Steven E. Fleck's experience

Training of Steven E. Fleck

Northern Illinois University	Masters Business Admin
University of Illinois	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Steven E. Fleck's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Northfield Laboratories, Inc. Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage.	Health Technology
CDG Therapeutics, Inc. CDG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology CDG Therapeutics, Inc. develops pharmaceutical products. Its peptides are derived from bacterial & plant sources and are selective for certain cancers while avoiding healthy cells. The company was founded by Ananda M. Chakrabarty and Tapas K. Das Gupta in May 2001 and is located in River Forest, IL.	Health Technology